TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the ...

The MarketWatch News Department was not involved in the creation of this content. BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage ...

Decoy Therapeutics Inc. , a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs tm), a new category of antivirals engineered to target shared viral mechanisms using ...

BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (RNAZ) (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and ...

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.

Countries that invested in seasonal influenza vaccination programs for health workers prior to the COVID-19 pandemic were significantly better positioned to deploy COVID-19 vaccines rapidly and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Kailera Therapeutics, Inc. (KLRA) has filed to raise capital to continue its development efforts, according to an S-1 registration statement. The company is a clinical-stage biopharma developing GLP-1 ...

Neurocrine Biosciences NBIX-1.93%decrease; red down pointing triangle agreed to buy Soleno Therapeutics SLNO-0.21%decrease; red down pointing triangle for $2.9 billion, giving it the first approved ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor. Proceeds from the financing will support ...

Soleno shares jump nearly 33% after deal announcement Neurocrine CEO says no immediate plans for Vykat XR launch in Europe Cantor analysts project Vykat XR sales to exceed $1 billion by 2029 The deal ...